China’s Jiangsu Aidea eyes Hong Kong IPO as gateway to US, European Aids marketsSCMP·Mar 26 at 12:31 AM002675+0.23%江苏鼎泰药物研究(集团)股份有限公司
The A-share innovative drug concept fluctuated and declined, with SDKX falling over 10%. INNOSTAR, HITECK, Aidea Pharma, Chemexpress, and Beilu Pharma had significant declinesWallstreetcn·Mar 19 at 01:30 AM300016+2.63%688136+3.63%
Aidea Pharma: Sodium Dolutegravir API receives approval for listing applicationZhitong·Oct 27, 2025 at 05:09 AM688488+2.22%
Aidea Pharma: The full text of the 96-week study on Fubangde® SPRINT was published in BMC MedicineZhitong·Oct 10, 2025 at 07:13 PM688488+2.22%
Aidea Pharma: Ainomit Tablets Obtains Drug Registration Certificate in ZanzibarZhitong·Jul 27, 2025 at 02:53 AM688488+2.22%
New regulations for national HIV drug resistance research released, Aidea Pharma deeply involvedWallstreetcn·Jul 6, 2025 at 07:38 AM688488+2.22%
Aidea Pharma plans to launch a stock option incentive plan for 11.375 million sharesZhitong·Jun 27, 2025 at 07:15 AM688488+2.22%
The biopharmaceutical sector continues to adjust, with *ST Four Rings hitting the daily limit down, Rongchang Bio falling over 18%, and Mabwell, SDKX, Science Sun Pharm, OPM, Aidea Pharma, and others following suitZhitong·Jun 26, 2025 at 01:17 AM688293-2.72%688488+2.22%
Aidea Pharma: Termination of the framework contract for the cooperative development of new drug projects with PharmaronZhitong·Apr 8, 2025 at 04:22 AM688488+2.22%
Three major benefits suddenly arrive! This sector has completely exploded!USHK News·Mar 31, 2025 at 11:29 PM688222+4.98%688488+2.22%
The first overseas GMP certificate Aidea Pharma obtained the Zanzibar GMP certificateZhitong·Mar 14, 2025 at 08:11 PM688488+2.22%
Aidea Pharma: Phase I clinical trial approval granted for the investigational 2.2 class modified new drug AD108 injectionZhitong·Mar 13, 2025 at 05:03 AM688488+2.22%
Aidea Pharma's net loss for the year 2024 is 130 million yuanZhitong·Feb 27, 2025 at 08:49 AM688488+2.22%
Aidea Pharma issued a profit warning, expecting a net loss of approximately 95 million to 143 million yuan for the fiscal year 2024, with losses wideningZhitong·Jan 17, 2025 at 05:16 AM688488+2.22%
Aidea Pharma's actual controller and president have cumulatively increased their holdings in the company by 762,700 sharesZhitong·Dec 27, 2024 at 05:29 AM688488+2.22%
